halcinonide and Psoriasis

This prospective, open-label study evaluated the effectiveness and safety of tildrakizumab plus topical halcinonide ointment in psoriasis patients.. Adults (age greater than or equal to 18 years) with moderate to severe plaque psoriasis (body surface area [BSA] greater than or equal to 10%, physician's global assessment [PGA] greater than or equal to 3, psoriasis area severity index [PASI] greater than or equal to 12) received tildrakizumab (100 mg; s.c.) at weeks 0, 4, and 16. Patients with BSA >3% at week 16 received additional halcinonide 0.1% twice daily for 4 weeks (week 20) and were followed for another 4 weeks (week 24); those with BSA less than or equal to 3% were followed to week 24.. Twenty-five patients were enrolled (mean age 52.6 years; 68% male). The proportion of all patients achieving BSA less than or equal to 3% was 52.2% at week 16, 73.7% at week 20 (after 4 weeks of adjunctive halcinonide in patients with BSA >3% at week 16), and 84.2% at week 24 (4 weeks after halcinonide discontinuation). PASI 75 was attained in 60.9% of all patients at week 16, and 73.7% at weeks 20 and 24. In patients adding halcinonide, improvements from baseline in mean BSA, PGA, and PGA x BSA increased from week 16 (55%, 29%, and 64%, respectively) to week 20 (78%, 51%, and 88%, respectively), and were maintained through week 24. Quality of life improved with tildrakizumab monotherapy and further with adjunctive halcinonide. Adverse events (AEs) were infrequent. No serious AEs or discontinuations due to AEs were noted.. Tildrakizumab plus topical halcinonide ointment is safe and effective in controlling psoriasis for patients inadequately responding to tildrakizumab monotherapy.Bagel J, Novak K, Nelson E. Tildrakizumab in combination with topical halcinonide 0.1% ointment for treating moderate to severe plaque psoriasis. J Drugs Dermatol. 2023;22(8):766-772. doi:10.36849/JDD.6830.

Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Halcinonide; Humans; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome

The use of the Actiderm dermatological patch in conjunction with topical corticosteroids was evaluated in a multi-centered, paired-comparison study of 189 patients with chronic psoriasis. In each patient, two lesions of comparable severity were selected for treatment. One plaque was treated with a twice-daily application of a steroid cream (triamcinolone acetonide 0.1 percent, betamethasone valerate 0.1 percent, or halcinonide 0.1 percent) while the second plaque was treated with a forty-eight hour application of the same steroid cream under Actiderm. At follow-up visits during the three-week treatment period and at four weeks post-treatment, the lesions were evaluated for the following parameters: erythema, induration, scale, and fissuring. For each of the three steroid preparations, the Actiderm and steroid therapy produced significant improvement in all parameters compared to the steroid therapy alone. This improvement was sustained through the post-treatment phase (p is less than 0.05 in all groups). No measurable differences in therapeutic efficacy were identified among the three steroid groups. Reports of adverse experiences in the Actiderm and steroid groups were infrequent. We conclude that the Actiderm and steroid combination is a safe and highly effective treatment for psoriasis.

Topics: Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Betamethasone; Chronic Disease; Female; Halcinonide; Humans; Male; Middle Aged; Multicenter Studies as Topic; Occlusive Dressings; Pharmaceutical Vehicles; Psoriasis; Triamcinolone Acetonide

Topics: Betamethasone; Clinical Trials as Topic; Clobetasol; Consumer Behavior; Double-Blind Method; Evaluation Studies as Topic; Halcinonide; Humans; Ointments; Pregnenediones; Psoriasis; Random Allocation

Topics: Administration, Topical; Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Halcinonide; Humans; Male; Middle Aged; Ointments; Pregnenediones; Psoriasis; Random Allocation; Triamcinolone

Topics: Clinical Trials as Topic; Clobetasol; Dermatitis; Halcinonide; Humans; Pregnenediones; Psoriasis

A double-blind paired comparison was made of once daily and three times daily regimens of 0.1% halcinonide cream in 149 patients with atopic dermatitis and 194 with psoriasis. In a simultaneously conducted study once daily application of 0.1% halcinonide was compared to the cream base alone (placebo) in 48 patients with atopic dermatitis and 78 with psoriasis. Results show that a once daily regimen can be an effective treatment in both conditions, and can be recommended as a starting regimen in certain circumstances such as the treatment of young children or pregnant women, or where long-term treatment is likely. The three times daily regimen, however, was superior overall, and is still recommended as the treatment of choice, at least in severe psoriasis.

Topics: Administration, Topical; Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic; Double-Blind Method; Female; Halcinonide; Humans; Infant; Male; Middle Aged; Pregnenediones; Psoriasis

In a double-blind multi-centre study, comprising ninety-five patients with psoriasis and atopic dermatitis, 0.1% halcinonide cream applied once daily was equally as effective as the cream applied three times daily. However, the onset of action was more rapid when the cream was applied three times daily. In a control study once daily application of 0.1% halcinonide cream was found to be superior to the vehicle alone in the treatment of forty patients with the same diseases.

Topics: Administration, Topical; Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic; Double-Blind Method; Drug Administration Schedule; Evaluation Studies as Topic; Female; Halcinonide; Humans; Infant; Male; Middle Aged; Placebos; Pregnenediones; Psoriasis; Time Factors

Data were reviewed on the beneficial responses and adverse reactions among 2,849 patients in 14 paired-comparison studies with eight unoccluded topical corticosteroids in six steroid-responsive dermatoses. Adverse reactions were found to be mild, transient, and, for the most part, rare. Of 5,698 treatment exposures, 249 (4.39%) adverse reactions were reported, including irritation (1.3%), itching (0.95%), burning (0.81%), dryness (0.46%), scaling (0.30%), and vesicle formation (0.16%). Other reactions occurred in less than one in 1,000 treatment exposures. No severe reactions were observed. Five subjects (0.17%) terminated treatment early because of adverse reactions. The incidence of adverse reactions to vehicle alone was 6.7%. The benefit-risk ratio for mild reactions was 17:1. Therefore, long lists of adverse reactions are inappropriate in written consent forms for prospective volunteers for clinical trials. Al alternative warning statement is proposed.

Topics: Administration, Topical; Anti-Inflammatory Agents; Clinical Trials as Topic; Dermatitis, Atopic; Dermatitis, Contact; Double-Blind Method; Female; Fluocinonide; Glucocorticoids; Halcinonide; Humans; Male; Psoriasis; Skin Diseases

A comparative trial between betamethasone valerate and halcinonide has shown the former to be superior, thus contradicting the results from other trials. It is thought that the discrepancy is due to differences in the nature of the preparations used in the various studies. It is suggested that note is made of the base used in trials before final conclusions about the efficicacy of steroids are made.

Topics: Administration, Topical; Betamethasone; Betamethasone Valerate; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Eczema; Halcinonide; Humans; Ointments; Psoriasis; Skin Diseases

Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Halcinonide; Humans; Male; Middle Aged; Pregnenediones; Psoriasis

Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Eczema; Erythema; Female; Halcinonide; Humans; Lichen Planus; Male; Middle Aged; Ointments; Parapsoriasis; Pityriasis; Pregnenediones; Psoriasis; Skin Diseases